A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR-Reference-Cited by-同舟云学术

A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

Published:2016-04-01 Issue:8 Volume:23 Page:1380-1393
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Tosco A,De Gregorio F,Esposito S,De Stefano D,Sana I,Ferrari E,Sepe A,Salvadori L,Buonpensiero P,Di Pasqua A,Grassia R,Leone C A,Guido S,De Rosa G,Lusa S,Bona G,Stoll G,Maiuri M C,Mehta A,Kroemer G,Maiuri L,Raia V

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cdd201622.pdf

Reference47 articles.

1. Ratjen F, Döring G . Cystic fibrosis. Lancet 2003; 361: 681–689.

2. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L . The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 2014; 13: 403–409.

3. Ramsey BW, Davies J, McElvaney NG, Bell SC, Drevinek P, Griese M et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663–1672.

4. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M et alTRAFFIC and TRANSPORT Study Groups. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220–231.

5. Boyle A MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E et al. VX09-809-102 study group. CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2: 527–538.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases;Biomedicine & Pharmacotherapy;2024-09

2. Autophagy and Senescence: The Molecular Mechanisms and Implications in Liver Diseases;International Journal of Molecular Sciences;2023-11-28

3. New alternative therapeutic strategies against Pseudomonas aeruginosa, an opportunistic multi-resistant pathogen with a myriad of virulence factors;The Journal of Infection in Developing Countries;2023-07-27

4. Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications;Molecules;2023-07-06

5. Cytoplasmic YAP1‐mediated ESCRT‐III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer;Cancer Communications;2023-04-02